C S Lau1, S P Hoo1, Y L Liang1, S K Phua1, T C Aw1,2,3. 1. Department of Laboratory Medicine, Changi General Hospital, Singapore. 2. Department of Medicine, National University of Singapore, Singapore. 3. Academic Pathology Program, Duke-NUS Medical School, Singapore.
Abstract
INTRODUCTION: We evaluated two SARS-CoV-2 antibody point-of-care tests (POCTs) (Abbott Panbio COVID-19 IgG/IgM and Roche SARS-CoV-2 Rapid Antibody tests) and compared the results to their respective chemiluminescent immunoassays (CLIAs) (Abbott Architect IgM, Architect IgG, Roche Cobas total antibody assays). METHOD: 200 pre-pandemic sera and 48 samples positive for various conditions (18 viral hepatitis, 18 dengue, 11 ANA and 1 dsDNA) were used as controls and to assess for cross-reactivity. Anonymised residual leftover sera positive for SARS-CoV-2 on RT-PCR were recruited as cases (n = 133). The sensitivity/specificity/cross-reactivity/positive predictive value (PPV)/negative predictive value (NPV) of the POCTs were assessed. Concordance between the POCTs and chemiluminescent immunoassays (CLIAs) were analysed. RESULTS: Abbott/Roche POCT specificity was 98.7%/100% (95% CI 96.5-99.8/98.5-100) and sensitivity was 97.2%/97.2% (95% CI 85.5-99.9/85.5-99.9) in cases ≥14 days post-first positive RT-PCR (POS), PPV was 68.7%/100% (95% CI 41.3-87.2/94.7-100.0), and NPV was 97.4%/97.6% (95% CI 97.0-97.8/97.2-98.0). In cases ≥14 days POS, concordance of Abbott/Roche POCT and CLIAs was 97.2%/100% (35/36 and 36/36 results). The sensitivity of individual IgM-band results on both POCTs did not increase >95% even after 14 days POS (Abbott 2.78%, Roche 44.4%). CONCLUSION: Both POCTs have good specificity, little cross-reactivity with other antibodies, and sensitivity >95% when used in subjects ≥14 days POS. Analysis of individual POCT IgG/IgM-bands did not provide any additional information. POCTs can substitute for CLIAs in cases ≥14 days POS. In low prevalence areas, POCTs would be especially useful when combined with antigen testing in an orthogonal format to increase the PPV of COVID-19 results.
INTRODUCTION: We evaluated two SARS-CoV-2 antibody point-of-care tests (POCTs) (Abbott Panbio COVID-19 IgG/IgM and Roche SARS-CoV-2 Rapid Antibody tests) and compared the results to their respective chemiluminescent immunoassays (CLIAs) (Abbott Architect IgM, Architect IgG, Roche Cobas total antibody assays). METHOD: 200 pre-pandemic sera and 48 samples positive for various conditions (18 viral hepatitis, 18 dengue, 11 ANA and 1 dsDNA) were used as controls and to assess for cross-reactivity. Anonymised residual leftover sera positive for SARS-CoV-2 on RT-PCR were recruited as cases (n = 133). The sensitivity/specificity/cross-reactivity/positive predictive value (PPV)/negative predictive value (NPV) of the POCTs were assessed. Concordance between the POCTs and chemiluminescent immunoassays (CLIAs) were analysed. RESULTS: Abbott/Roche POCT specificity was 98.7%/100% (95% CI 96.5-99.8/98.5-100) and sensitivity was 97.2%/97.2% (95% CI 85.5-99.9/85.5-99.9) in cases ≥14 days post-first positive RT-PCR (POS), PPV was 68.7%/100% (95% CI 41.3-87.2/94.7-100.0), and NPV was 97.4%/97.6% (95% CI 97.0-97.8/97.2-98.0). In cases ≥14 days POS, concordance of Abbott/Roche POCT and CLIAs was 97.2%/100% (35/36 and 36/36 results). The sensitivity of individual IgM-band results on both POCTs did not increase >95% even after 14 days POS (Abbott 2.78%, Roche 44.4%). CONCLUSION: Both POCTs have good specificity, little cross-reactivity with other antibodies, and sensitivity >95% when used in subjects ≥14 days POS. Analysis of individual POCT IgG/IgM-bands did not provide any additional information. POCTs can substitute for CLIAs in cases ≥14 days POS. In low prevalence areas, POCTs would be especially useful when combined with antigen testing in an orthogonal format to increase the PPV of COVID-19 results.
Authors: Mary Kathryn Bohn; Tze Ping Loh; Cheng-Bin Wang; Robert Mueller; David Koch; Sunil Sethi; William D Rawlinson; Massimo Clementi; Rajiv Erasmus; Marc Leportier; Matthias Grimmler; K Y Yuen; Nicasio Mancini; Gye Cheol Kwon; María Elizabeth Menezes; Maria-Magdalena Patru; Maurizio Gramegna; Krishna Singh; Osama Najjar; Maurizio Ferrari; Andrea R Horvath; Giuseppe Lippi; Khosrow Adeli Journal: Clin Chem Lab Med Date: 2020-10-07 Impact factor: 3.694
Authors: Lauren M Kucirka; Stephen A Lauer; Oliver Laeyendecker; Denali Boon; Justin Lessler Journal: Ann Intern Med Date: 2020-05-13 Impact factor: 25.391
Authors: Jacqueline Dinnes; Jonathan J Deeks; Ada Adriano; Sarah Berhane; Clare Davenport; Sabine Dittrich; Devy Emperador; Yemisi Takwoingi; Jane Cunningham; Sophie Beese; Janine Dretzke; Lavinia Ferrante di Ruffano; Isobel M Harris; Malcolm J Price; Sian Taylor-Phillips; Lotty Hooft; Mariska Mg Leeflang; René Spijker; Ann Van den Bruel Journal: Cochrane Database Syst Rev Date: 2020-08-26
Authors: Daniel F Gudbjartsson; Gudmundur L Norddahl; Pall Melsted; Kristbjorg Gunnarsdottir; Hilma Holm; Elias Eythorsson; Asgeir O Arnthorsson; Dadi Helgason; Kristbjorg Bjarnadottir; Ragnar F Ingvarsson; Brynja Thorsteinsdottir; Steinunn Kristjansdottir; Kolbrun Birgisdottir; Anna M Kristinsdottir; Martin I Sigurdsson; Gudny A Arnadottir; Erna V Ivarsdottir; Margret Andresdottir; Frosti Jonsson; Arna B Agustsdottir; Jonas Berglund; Berglind Eiriksdottir; Run Fridriksdottir; Elisabet E Gardarsdottir; Magnus Gottfredsson; Olafia S Gretarsdottir; Steinunn Gudmundsdottir; Kjartan R Gudmundsson; Thora R Gunnarsdottir; Arnaldur Gylfason; Agnar Helgason; Brynjar O Jensson; Aslaug Jonasdottir; Hakon Jonsson; Thordur Kristjansson; Karl G Kristinsson; Droplaug N Magnusdottir; Olafur T Magnusson; Lovisa B Olafsdottir; Solvi Rognvaldsson; Louise le Roux; Gudrun Sigmundsdottir; Asgeir Sigurdsson; Gardar Sveinbjornsson; Kristin E Sveinsdottir; Maney Sveinsdottir; Emil A Thorarensen; Bjarni Thorbjornsson; Marianna Thordardottir; Jona Saemundsdottir; S Hjortur Kristjansson; Kamilla S Josefsdottir; Gisli Masson; Gudmundur Georgsson; Mar Kristjansson; Alma Moller; Runolfur Palsson; Thorolfur Gudnason; Unnur Thorsteinsdottir; Ingileif Jonsdottir; Patrick Sulem; Kari Stefansson Journal: N Engl J Med Date: 2020-09-01 Impact factor: 91.245
Authors: Barnaby Flower; Jonathan C Brown; Wendy S Barclay; Graham S Cooke; Bryony Simmons; Maya Moshe; Rebecca Frise; Rebecca Penn; Ruthiran Kugathasan; Claire Petersen; Anna Daunt; Deborah Ashby; Steven Riley; Christina Joanne Atchison; Graham P Taylor; Sutha Satkunarajah; Lenny Naar; Robert Klaber; Anjna Badhan; Carolina Rosadas; Maryam Khan; Natalia Fernandez; Macià Sureda-Vives; Hannah M Cheeseman; Jessica O'Hara; Gianluca Fontana; Scott J C Pallett; Michael Rayment; Rachael Jones; Luke S P Moore; Myra O McClure; Peter Cherepanov; Richard Tedder; Hutan Ashrafian; Robin Shattock; Helen Ward; Ara Darzi; Paul Elliot Journal: Thorax Date: 2020-08-12 Impact factor: 9.102
Authors: Johann Bartko; Sonja Zehetmayer; Lukas Weseslindtner; Karin Stiasny; Andrea Schloegl; Ernst Forjan; Elisabeth Zwettler; Andreas Krauter; Felix Keil; Nazanin Sédille-Mostafaie Journal: J Clin Med Date: 2021-04-28 Impact factor: 4.241